Answering important clinical questions — such as whether genetic diversity is a risk factor for
aggressive tumor development or how it relates to treatment resistance — requires analyzing samples from many patients with different types of cancer.
Not exact matches
An experimental drug in early
development for
aggressive brain
tumors can cross the blood - brain
tumor barrier, kill
tumor cells and block the growth of
tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James).
Recently, teaming up with co-investigator Associate Professor Dr. Rolf A. Brekken, they looked into its possible involvement in Pancreatic Ductal Adenocarcinoma (PDA), the most common form of pancreatic cancer, in a mouse model with an early onset
aggressive form of
tumor development.
As this variant also appears to be associated with the
development of more
aggressive prostate
tumors, a diagnostic test for the variant may enable doctors to make more informed decisions as to how closely they should monitor those who are at high risk, and how aggressively they should treat the disease once it presents.
These two aspects of
tumor progression (hypoxia and reoxygenation) cooperate to provide growth advantages essential for the progressive
development of
aggressive tumors [21].
It has been postulated that hypoxia contributes directly to the
development of more
aggressive cancers by exerting selective pressure on the
tumor cell population to favor cells that can survive decreased O2 and nutrients [18 — 20].
«This has important implications for
tumor development because certain cells might be more
aggressive than others,» Beck said.